Precision BioSciences Inc (FRA:PBS0)
€ 9.85 -0.25 (-2.48%) Market Cap: 65.13 Mil Enterprise Value: -34.23 Mil PE Ratio: 0 PB Ratio: 2.02 GF Score: 56/100

Cell Gene Meeting on the Mesa - Precision BioSciences Transcript

Jan 08, 2021 / NTS GMT
Release Date Price: €234 (+5.41%)
Cindy Atwell
Precision Biosciences, Inc. - Chief Business Officer

Hello. My name is Cindy Atwell, and I'm VP of Business Development at Precision BioSciences. We are a clinical stage biotechnology company leveraging a next-generation genome editing platform for the development of therapeutics. We are a public company and I will be making forward-looking statements today. Please refer to the disclosures and risk factors in our SEC filings.

Precision BioSciences is dedicated to improving life through the application of our proprietary ARCUS genome editing platform. The focus of Precision BioSciences is to create therapeutics that address unmet medical needs.

Applying ARCUS, we are seeking to overcome cancer through the development of allogeneic CAR T therapies and the cure of rare diseases through in vivo gene correction. Our wholly owned subsidiary, Elo Life Systems also placed the ARCUS platform to improve human health through food. It has been an exciting year at Precision during which we have built a world-class team of 220 employees. We've established a GMP manufacturing facility and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot